RVTY250117P105000
- 2.35
- 0.000.00%
Revvity Newsroom
Express News | Revvity Inc : Jefferies Cuts Target Price to $120 From $125
UBS Says 'Underweight the Names With High China Exposure'
China Neurogenomics Market Research 2024-2031, Profiles of Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche, MGI Tech, Agilent, Revvity, Qiagen, Pacific Biosciences, Danaher, Oxford Nanopore - ResearchAndMarkets.com
Does Revvity (NYSE:RVTY) Have A Healthy Balance Sheet?
Citi Maintains Revvity(RVTY.US) With Buy Rating, Maintains Target Price $145
Revvity's Strategic Market Position and Anticipated Growth Drive Buy Rating
Revvity to Present at J.P. Morgan Healthcare Conference
BofA Securities Upgrades Revvity(RVTY.US) to Buy Rating, Announces Target Price $138
BofA Securities Upgrades Revvity to Buy From Neutral
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Revvity (RVTY) and McKesson (MCK)
What You Can Learn From Revvity, Inc.'s (NYSE:RVTY) P/E
Gene Editing Market Forecast Report 2024, With Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More
Stifel Nicolaus Remains a Hold on Revvity (RVTY)
What Are Wall Street Analysts' Target Price for Revvity Stock?
Revvity Is Maintained at Overweight by Barclays
Revvity Analyst Ratings
Barclays Maintains Revvity(RVTY.US) With Buy Rating, Cuts Target Price to $135
Barclays Adjusts Price Target on Revvity to $135 From $140, Keeps Overweight Rating
Revvity (RVTY) Receives a Buy From Barclays
Strategic Growth and Innovation Drive Puneet Souda's Buy Rating for Revvity